Skip to content

Evaluation of Advanced US Tools in Assessing Allograft Complications

The Evaluation of Advanced Ultrasonography Applications in the Assessment of Transplanted Kidney Complications

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04423458
Enrollment
80
Registered
2020-06-09
Start date
2022-01-04
Completion date
2022-09-30
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure, Chronic Kidney Diseases, Failure,Kidney, Renal Artery Stenosis, Fibrosis, Complications

Keywords

3D Ultrasound, US elastography, US MFI, Ultrasound, MRI, CT

Brief summary

This study evaluates the role of advanced US technology in assessing renal transplants as screening tools such as 3D Ultrasound, Ultrasound SWE, and MFI besides current ultrasound conventional metheds.

Detailed description

This study will focus on monitoring renal after transplantation using all US advanced technology. Aim one will concentrate on the 3D US in assessing artery stenosis (TRAS) compared to the gold standard. Aim two focuses on will concentrate on Ultrasound elastography in assessing renal stiffness. Aim three will compare US colour modes such as PD, CD and MFI to assess renal perfusion in three groups. Duration: 18 Months; participants will have a patient information sheet; once they are happy to participate, consent will be obtained. Study data will be entered into a database encrypted and stored in the department. Only the study principal investigator (PI) will know the study database password.

Interventions

The study will focus on the accuracy of ultrasound technology in assessing renal transplants. The entire assessment should not take more than 25 minutes.

Sponsors

Imperial College London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients ≥ 18 years. * Tx patients. * Gender.

Exclusion criteria

* Prisoners. * Patients \< 18 years. * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Peak systolic velocity ratio (PSVR).12 weeksHigh velocity flow at the stenosis site divided by a reference velocity (normal before stenosis)
Resistive Index (RI).12 weeksAn RI less than 0.7 to 0.8 is considered normal, more than that it is indicator of transplant dysfunction.
Peak systolic velocity (cm/s).12 weeksPean of the blood flow velocities in the artery/ vein peak systolic velocity ≥200 cm/s velocity difference between pre- and post-stenotic segments of 2:1

Secondary

MeasureTime frameDescription
Volumetric stenosis.12 weeksPlaque volume is calculated automatically with the aid of software with a package of 3D laptop.
3D GSM.12 weeksPlaque volume is calculated automatically with the aid of software with a package of 3D laptop.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026